All News

The approval of remibrutinib for patients with chronic spontaneous urticaria was supported by data from the phase 3 REMIX-1 and REMIX-2 clinical trials.

Immune gene signatures were linked to illness severity and treatment response in sepsis and other critical conditions.

Tory M. Wolff, MBA, discusses his study showing that frequent routine primary care visits may lower costs for higher-risk commercially insured adults.

Second primary malignancies in patients with small cell lung cancer are often misdiagnosed as distant metastases.

Electronic health record (EHR)–based “e-phenotypes” combining lab data, coding, and AI could dramatically improve early detection and management of chronic kidney disease.

Oncology care requires teamwork, support services, and careful planning to ensure effective, affordable, and patient-focused treatment, according to Brian Mulherin, MD.

Prior authorizations can affect both health system operations and worsen physician burnout.

Clinician's role in breast cancer care and access with reproductive and urinary oncologist Lakshminarayanan Nandagopal, MD

Experian Health’s 2025 State of Claims survey shows rising denial rates, data errors, and low artificial intelligence adoption despite providers’ belief in its potential.

An increase in opioid use disorder was found in those who had commercial insurance, with those aged 31 to 40 years having the highest percentage of opioid use disorder.

At the European Respiratory Society Congress, experts explored the critical connections between climate change, respiratory health, and health equity, highlighting the importance of integrated solutions, local action, and education.

Experts at the ERS Congress 2025 highlighted threats to scientific integrity from misinformation, political interference, and predatory publishing in health research.

Experts at European Respiratory Society (ERS) Congress 2025 highlight the critical link between reduced lung function and increased cardiovascular disease risk, urging early intervention and awareness.

Raludotatug deruxtecan (R-DXd) earned FDA breakthrough designation for CDH6-expressing platinum-resistant ovarian cancers after bevacizumab (Avastin; Genentech) treatment.

Advancements in breast cancer care and treatments with reproductive and urinary oncologist Lakshminarayanan Nandagopal, MD.

There are clear benefits to starting biologic therapy earlier for severe asthma, as well as initiation patterns by ethnicity, according to data at ERS Congress 2025.

Guselkumab becomes the first interleukin-23 inhibitor approved for children with plaque psoriasis or active psoriatic arthritis.

Ana Baramidze, MD, head of the Department of Clinical Researches at the Todua Clinic in Tbilisi, Georgia, explained how clinicians can decide how to cemiplimab, which has a low discontinuation rate.

Expanding community-based cancer services brings advanced treatments closer to home and addresses social determinants of health, says Kathy Oubre, MS.

Digital health technologies enhance respiratory care through decentralized clinical trials and home monitoring, expanding access and improving patient engagement.

Davey Daniel, MD, shares strategies to prevent bias in artificial intelligence (AI) and outlining future opportunities for its adoption in precision oncology.

High-risk patients who cannot find a matched sibling or matched unrelated donor may achieve a similar benefit from a haploidentical donor.

Oral upadacitinib combined with topical ruxolitinib cream may be a promising therapeutic approach for patients with progressive nonsegmental vitiligo.

Nerandomilast shows promise in treating progressive pulmonary fibrosis, demonstrating significant benefits in lung function and safety in recent trials.

Experts debate e-cigarettes' role in smoking cessation and public health at ERS Congress 2025, weighing benefits against potential risks and regulatory needs.

Treating constipation with lubiprostone may confer renal benefits in chronic kidney disease by modulating microbiome-driven pathways.

Findings suggest bispecific CD3xCD20 therapy may offer an option for patients with Richter syndrome who are ineligible for transplant or CAR T-cell Therapy.